Open drug discovery in Alzheimer's disease

Alzheimer's disease (AD) drug discovery has focused on a set of highly studied therapeutic hypotheses, with limited success. The heterogeneous nature of AD processes suggests that a more diverse, systems‐integrated strategy may identify new therapeutic hypotheses. Although many target hypothese...

Descripción completa

Detalles Bibliográficos
Autores principales: Axtman, Alison D., Brennan, Paul E., Frappier‐Brinton, Tristan, Betarbet, Ranjita, Carter, Gregory W., Fu, Haian, Gileadi, Opher, Greenwood, Anna K., Leal, Karina, Longo, Frank M., Mangravite, Lara M., Edwards, Aled M., Levey, Allan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192886/
https://www.ncbi.nlm.nih.gov/pubmed/37215505
http://dx.doi.org/10.1002/trc2.12394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192886/
https://www.ncbi.nlm.nih.gov/pubmed/37215505
http://dx.doi.org/10.1002/trc2.12394

Ejemplares similares